Company news

Immunic, Inc. news in 2025

Immunic, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

November 26, 2025

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Immunic to Participate in Industry and Investor Conferences in November

October 29, 2025

Immunic to Participate in Scientific and Investor Conferences in October

October 1, 2025

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

September 25, 2025

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

September 9, 2025

Immunic to Participate in Investor and Scientific Conferences in September

September 4, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

June 24, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

June 5, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

June 3, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June

June 2, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

April 30, 2025

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

April 10, 2025

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

April 9, 2025

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

April 1, 2025

Immunic to Participate in Scientific and Investor Conferences in March

March 3, 2025

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

February 26, 2025

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

February 20, 2025

Immunic to Participate in Investor and Scientific Conferences in February

February 3, 2025

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

January 6, 2025

Decks in 2025